RobertJ.BeltMD

PubMed

• Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cel...
  Sequist, L.V., Fidias, P.M., Temel, J.S., Kolevska, T., Rabin, M.S., Boccia, R.V., Burris, H.A., Belt, R.J., Huberman, M.S., Melnyk, O., Mills, G.M., Englund, C.W., Ca...> ;J Thorac Oncol. 2009-11-01
• 79 citations
  Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Ly...
  Sven de Vos, Andre Goy, Shaker R. Dakhil, Mansoor N. Saleh, Peter McLaughlin, R. J. Belt, Christopher R. Flowers, Mark Knapp, Lowell L. Hart, Dipti Patel-Donnelly, Mar...> ;Journal of Clinical Oncology. 2009 Oct 20
• Gemcitabine and Pemetrexed Administered in Rapid Sequence as Front-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Phase II Clinical Trial
  R J Belt, C Obasaju, H L West> ;British Journal of Anaesthesia. 2009 May 01
• 19 citations
  Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation
  Joseph McGuirk, Gang Hao, Weijian Hou, Sunil Abhyankar, Casey Williams, Weisi Yan, Jianda Yuan, Xiuqin Guan, Robert Belt, Shaun DeJarnette, Jeffery Wieman, Ying Yan> ;Journal of Hematology & Oncology. 2009 Apr 20
• Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
  Saltz, L.B., Rosen, L.S., Marshall, J.L., Belt, R.J., Hurwitz, H.I., Eckhardt, S.G., Bergsland, E.K., Haller, D.G., Lockhart, A.C., Rocha Lima, C.M., Huang, X., DePrim...> ;J Clin Oncol. 2007 Oct 20
• Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCL...
  West HJ, Belt RJ, Wakelee HA, Monberg MJ, Frye LA, Ye Z, Obasaju CK> ;J. Clin. Oncol.. 2006-06-20
• Destructive facial T-cell lymphoma: the difficulty in diagnosis of pyoderma-like processes.
  Lawrence E. Gibson, Bethany R. Hairston, Robert J Belt, Rokea A. el-Azhary> ;International Journal of Dermatology. 2005 Jul 1
• Preliminary results of a phase 2 study of ABT-751 in patients (pts) with taxane-refractory non-small cell lung carcinoma (NSCLC).
  Mauer AM, Szeto L, Belt RJ, Schwartzberg LS, Hagey A, Coates AI, Meek KA, Cernohous P, Gordon GB> ;J. Clin. Oncol.. 2005-06-01
• Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A phase 2 study.
  Fanucchi MP, Fossella F, Fidias P, Natale RB, Belt RJ, Carbone DP, Govindan R, Raez L, Robert F, Schiller J> ;J. Clin. Oncol.. 2005-06-01
• Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II cl...
  West H, Belt RJ, Wakelee HA, Bloss LP, Taylor L, Monberg MJ, Ye Z, Obasaju CK> ;J. Clin. Oncol.. 2005-06-01
• Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study.
  Goy A, Bernstein S, Kahl B, Epner E, Leonard JP, Stadtmauer E, Morgan D, Belt R, Baidas S, Fisher RI> ;J. Clin. Oncol.. 2005-06-01
• 55 citations
  A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lu...
  Miguel A. Villalona-Calero, Paul S. Ritch, Jose A. Figueroa, Gregory A. Otterson, Robert Belt, Edward Dow, Sebastian George, James M. Leonardo, Spence McCachren, G. La...> ;Clinical Cancer Research. 2004 Sep 15
• Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: A...
  Robert NJ, Leyland-Jones B, Asmar L, Belt RJ, Ilegbodu D, Loesch DM, Raju RN, Cobleigh M, Albain KS, Slamom DJ> ;J. Clin. Oncol.. 2004-07-15
• Results of a pilot trial of OSI-461 in patients with chronic lymphocytic leukemia.
  Reynolds CH, Raju RN, Vukelja SJ, Belt RJ, Hyman WJ, Boehm KA, Asmar L> ;J. Clin. Oncol.. 2004-07-15
• Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results.
  Fanucchi MP, Belt RJ, Fossella FV, Natale RB, Robert F, Fidias P, Kelly K, Kashala O, Schenkein DP, Schiller JH> ;J. Clin. Oncol.. 2004-07-15
• 11 citations
  Fourteen-Day CHOP Supported with Granulocyte Colony-Stimulating Factor in Patients with Aggressive Non-Hodgkin's Lymphoma: Results of a Phase II Study
  Stephanie A. Gregory, Linda D. Bosserman, Debra L. Litwak, William R. Berry, Leonard A. Kalman, Robert J. Belt, Alan Saven> ;Clinical Lymphoma. 2003 Sep 1
• 10 citations
  Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology G...
  Debra Hawes, P. Y. Liu, Franco M. Muggia, Sharon P. Wilczynski, Richard J. Cote, Juan C. Felix, Keith Terada, Robert J. Belt, David S. Alberts> ;Gynecologic Oncology. 2002 Oct 1
• 343 citations
  Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
  Lyndsay Harris, Gerald Batist, Robert Belt, Douglas Rovira, Rudolph Navari, Nozar Azarnia, Lauri Welles, Eric Winer> ;Cancer. 2002 Jan 1
• 18 citations
  Infusional interleukin‐2 and 5‐fluorouracil with subcutaneous interferon‐α for the treatment of patients with advanced renal cell carcinoma
  Laurence Elias, Danika Lew, Robert A. Figlin, Robert C. Flanigan, Mark E. Thompson, Pierre L. Triozzi, Robert J. Belt, David P. Wood, Saul E. Rivkin, E. David Crawford> ;Cancer. 2000 Aug 1
• 6 citations
  Sequential Biochemical Modulation of Fluorouracil With Folinic Acid, N-Phosphonacetyl-L-Aspartic Acid, and Interferon Alfa-2a in Advanced Colorectal Cancer
  Melanie E. Royce, William McGarry, Beth Bready, Shaker R. Dakhil, Robert J. Belt, J. Wendall Goodwin, Richard Gray, Paulo M. Hoff, Rodger J. Winn, Richard Pazdur> ;Journal of Clinical Oncology. 1999 Oct 1
• 12 citations
  Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma
  Dennis F. Moore, Richard Pazdur, James L. Abbruzzese, Jaffer A. Ajani, D. W. Dubovsky, James L. Wade, Robert J. Belt, C. Mangold, Beth Bready, Rodger J. Winn> ;Annals of Oncology. 1994 Mar 1
• 8 citations
  Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.
  Mark M. Zalupski, Jacqueline Benedetti, Stanley P. Balcerzak, Laura F. Hutchins, Robert J. Belt, Alexander Hantel, John Wendall Goodwin> ;Investigational New Drugs. 1993 Nov 1
• 39 citations
  Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma
  Richard Pazdur, Jaffer J. Ajani, James L. Abbruzzese, Robert J. Belt, Shaker R. Dakhil, Daniel Dubovsky, R N Suzanne Graham, R R N Susan Pilat, Rodger Winn, Bernard Levin> ;Cancer. 1992 Oct 15
• 18 citations
  A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.
  Richard Pazdur, Jaffer A. Ajani, Rodger J. Winn, James D. Bearden, Robert J. Belt, Susan Pilat, Rebecca Hallinan, Bernard Levin> ;Cancer. 1992 Feb 15
• 1 citations
  Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma.
  Frank V. Fossella, Rodger J. Winn, Paul Y. Holoye, Martin N. Raber, Larry Holden, Robert Belt, Heather Allen, Becky Hallinan, Karen Harper> ;Investigational New Drugs. 1991 Nov 1
• Join now to see all